SCHEMBL20149847

SCHEMBL20149847

COCCO[C@@H]1[C@H](C)[C@@H](CO)O[C@H]1n1cnc2c(NC(=O)c3ccccc3)ncnc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.51
ADORA1 P30542 6/20 0.50
ADORA3 P0DMS8 3/20 0.49
LMNA P02545 2/20 0.49
ADORA2A P29274 2/20 0.49
ADORA2B P29275 2/20 0.49
SLC29A1 Q99808 2/20 0.49
ALDH1A1 P00352 1/20 0.49
GLA P06280 1/20 0.49
PMP22 Q01453 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NPC1 O15118 1/20 0.49
NPY1R P25929 1/20 0.49
HTT P42858 1/20 0.49
NPY2R P49146 1/20 0.49
RAB9A P51151 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
CYP1A2 P05177 1/20 0.49
TSHR P16473 1/20 0.49
NFKB1 P19838 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19407980 1.00 PRMT6 (0.51) PRMT6ADORA1ADORA3LMNAADORA2A
SCHEMBL20149845 0.93 PRMT6 (0.51) PRMT6ADORA1P2RY12
SCHEMBL18464846 0.92 PRMT6 (0.53) PRMT6ADORA1ADORA3LMNAADORA2A
SCHEMBL26553789 0.92 PRMT6 (0.53) PRMT6ADORA1ADORA3LMNAADORA2A
SCHEMBL38653713 0.92 ADORA1 (0.56) ADORA1ADORA3LMNAADORA2AADORA2B
SCHEMBL19407591 0.92 ADORA1 (0.56) ADORA1ADORA3LMNAADORA2AADORA2B
SCHEMBL7064875 0.92 ADORA1 (0.56) ADORA1ADORA3LMNAADORA2AADORA2B
SCHEMBL7064871 0.92 ADORA1 (0.56) ADORA1ADORA3LMNAADORA2AADORA2B
SCHEMBL25966158 0.91 PRMT6 (0.52) PRMT6ADORA1ADORA3LMNAADORA2A
SCHEMBL25966132 0.90 PRMT6 (0.50) PRMT6ADORA1ADORA3LMNAADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250125-A1 NUCLEIC ACID POLYMERS JANSSEN BIOPHARMA, LLC 2023-08-10 US disclosed
US-20230203078-A1 SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS Janssen Biopharma, Inc. 2023-06-29 US disclosed
US-20180135054-A1 MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE ALIOS BIOPHARMA, INC. (US) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203078-A1 SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS NT5C3B, PNP, NME1 PRMT6 289/4885ADORA1 750/4885ADORA3 349/4885
US-20180135054-A1 MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE NSUN2, ADAR, POLM PRMT6 597/4885ADORA1 2193/4885ADORA3 985/4885
US-20230250125-A1 NUCLEIC ACID POLYMERS NSUN2, NSUN3, RNGTT PRMT6 606/4885ADORA1 3343/4885ADORA3 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.